Department of Plastic and Reconstructive Surgery, Korea University Guro Hospital, Seoul, South Korea.
Department of Plastic Surgery, Asan Medical Center, Seoul, South Korea.
Diabetes. 2019 Apr;68(4):837-846. doi: 10.2337/db18-0699. Epub 2019 Jan 24.
Mesenchymal stem cells (MSCs) may hold great promise for treating diabetic wounds. However, it is difficult for a clinician to use MSCs because they have not been commercialized. Meanwhile, a new commercial drug that contains adipose-derived stem cells (ASCs) has been developed. The purpose of this study was to examine the potential of allogeneic ASC sheets for treating diabetic foot ulcers. Fifty-nine patients with diabetic foot ulcers were randomized to either the ASC treatment group ( = 30) or a control group treated with polyurethane film ( = 29). Either an allogeneic ASC sheet or polyurethane film was applied on diabetic wounds weekly. These wounds were evaluated for a maximum of 12 weeks. Complete wound closure was achieved for 73% in the treatment group and 47% in the control group at week 8. Complete wound closure was achieved for 82% in the treatment group and 53% in the control group at week 12. The Kaplan-Meier median times to complete closure were 28.5 and 63.0 days for the treatment group and the control group, respectively. There were no serious adverse events related to allogeneic ASC treatment. Thus, allogeneic ASCs might be effective and safe to treat diabetic foot ulcers.
间充质干细胞（MSCs）在治疗糖尿病创面方面可能具有巨大的应用前景。然而，由于 MSCs 尚未商业化，临床医生难以应用它们。同时，一种含有脂肪来源干细胞（ASCs）的新型商业药物已经开发出来。本研究旨在探讨异体 ASC 片治疗糖尿病足溃疡的潜力。59 例糖尿病足溃疡患者被随机分为 ASC 治疗组（n = 30）或聚氨酯薄膜对照组（n = 29）。每周在糖尿病创面应用异体 ASC 片或聚氨酯薄膜。这些创面最多评估 12 周。第 8 周时，治疗组完全愈合的比例为 73%，对照组为 47%。第 12 周时，治疗组完全愈合的比例为 82%，对照组为 53%。Kaplan-Meier 中位完全愈合时间分别为治疗组 28.5 天和对照组 63.0 天。异体 ASC 治疗无严重不良事件。因此，异体 ASC 治疗糖尿病足溃疡可能是有效且安全的。
